Y i Xianzhong is the chairman of Bio-Thera Solutions, a Guangzhou-based biotechnology company he founded in 2003. The company specializes in the research and development of innovative drugs for the treatment of cancer, autoimmune diseases, and cardiovascular conditions. Yi holds a degree in computers and radio from the South China University of Technology. Before entering the biotech field, he founded Hedy Computer, a successful PC manufacturer that went public in 2004 and was later acquired.
Under Yi's leadership, Bio-Thera successfully listed on the Shanghai Stock Exchange's STAR Market in 2020. His transition from IT hardware to biopharmaceuticals highlights his versatility as an entrepreneur. Bio-Thera is known for developing biosimilars and novel antibody drugs, aiming to provide affordable and effective therapies to patients globally.
Advertisement
Yi Xianzhong is a Chinese businessman, the Chairman of Bio-Thera Solutions (SHA: 688177), which develops drugs to treat tumors and cardiovascular and autoimmune diseases.
Yi graduated from the South China University of Technology, where he majored in computers and radio. He worked for a state-owned firm in Guangzhou after graduation before founding his first company, computer maker Hedy Computer.
Yi Xianzhong’s career is marked by two distinct, successful ventures. He first made his fortune by founding Hedy Computer, which went public in 2004 before being acquired by Focus Media in 2016.
He then founded Bio-Thera Solutions, successfully pivoting to the biotech sector. Bio-Thera listed on the Shanghai Stock Exchange's Sci-Tech Innovation Board in February 2020. His structural contribution is tied to funding and guiding R&D for next-generation treatments in China's growing biotech market.
Advertisement
Founded Hedy Computer.
Hedy Computer goes public.
Hedy is acquired by Focus Media.
Bio-Thera Solutions lists on the Shanghai Stock Exchange's Sci-Tech Innovation Board.
Continues as Chairman of Bio-Thera Solutions.
Yi Xianzhong's wealth is concentrated in his founding equity in the publicly traded biotech firm, Bio-Thera Solutions.
Advertisement
Advertisement
No publicly available quotes.
Advertisement
0% | $0.00M
-1.75% | -$38.44M
This profile is compiled from verified biographical and financial records:
All information is cross-referenced with public sources for accuracy; some narrative sections are AI-assisted summaries.
If you find any inaccuracies, please report them to admin@redcarpetlife.in
Sponsored Content